Nerandomilast slows decline in forced vital capacity in idiopathic pulmonary fibrosis

For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), according to a study presented at CHEST 2025, the annual meeting of the American College of Chest Physicians, held from Oct. 19 to 22 in Chicago.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup